Utama › Aterosklerosis › New Jersey
Kajian klinikal Aterosklerosis di New Jersey
6 kajian untuk Aterosklerosis sedang mencari peserta di lokasi di New Jersey.
Bandar di New Jersey
Teks kajian rasmi (Bahasa Inggeris)
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
- Clinical Research of Philadelphia, Pennington
- Cardio Metabolic Institute, Somerset
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT07157774Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- CardioMetabolic Collaborative Clinic, Somerset
Mengambil pesertaFasa 3
Umur 45 hingga 99 · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07037433Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
- Hypertension & Nephrology Association, Eatontown
- New Jersey Kidney Care, Jersey City
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Sep 2026 · NCT05485961A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
- Research Site, Bridgewater
- Research Site, Elmer
- Research Site, Haddon Heights
- dan 2 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Ogo 2026 · NCT07000357Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
- Overlook Medical Center, Summit
Mengambil pesertaFasa 3
Umur 18 hingga 80 · Semua jantina · Dikemas kini 7 Ogo 2026 · NCT06813911Pelacarsen Roll-over Extension Program
- Robert Wood Johnson Medical School, New Brunswick
- Overlook Medical Center, Summit
Mengambil pesertaFasa 3
Umur 18 hingga 100 · Semua jantina · Dikemas kini 29 Jul 2026 · NCT06875973Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.